Application of thermoreversible hydrogel (poloxamer 407) to protect the corneal endothelium during phacoemulsification in porcine and rabbit eyes

2018 ◽  
Vol 44 (10) ◽  
pp. 1254-1260 ◽  
Author(s):  
Jung Yeol Choi ◽  
Chong-Su Cho ◽  
Young Keun Han
Keyword(s):  
Corneal Endothelium ◽  
Poloxamer 407 ◽  
Thermoreversible Hydrogel

scholarly journals Small molecule delivery across a perforated artificial membrane by thermoreversible hydrogel poloxamer 407

2019 ◽  
Vol 182 ◽  
pp. 110300 ◽  
Author(s):  
A. Santimetaneedol ◽  
Z. Wang ◽  
D.N. Arteaga ◽  
A. Aksit ◽  
C. Prevoteau ◽  
...  
Keyword(s):  
Small Molecule ◽  
Poloxamer 407 ◽  
Artificial Membrane ◽  
Thermoreversible Hydrogel

scholarly journals Mucoadhesive, Thermoreversible Hydrogel, Containing Tetracaine-Loaded Nanostructured Lipid Carriers for Topical, Intranasal Needle-Free Anesthesia

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1760
Author(s):  
Giovana Maria Fioramonti Calixto ◽  
Bruno Vilela Muniz ◽  
Simone R. Castro ◽  
Jaiza Samara Macena de Araujo ◽  
Klinger de Souza Amorim ◽  
...  
Keyword(s):  
Hybrid System ◽  
Neuroblastoma Cells ◽  
Fold Increase ◽  
Nanostructured Lipid Carriers ◽  
Poloxamer 407 ◽  
Tail Flick ◽  
Tail Flick Test ◽  
Hybrid Hydrogel ◽  
Thermoreversible Hydrogel

Recent advances have been reported for needle-free local anesthesia in maxillary teeth by administering a nasal spray of tetracaine (TTC) and oxymetazoline, without causing pain, fear, and stress. This work aimed to assess whether a TTC-loaded hybrid system could reduce cytotoxicity, promote sustained permeation, and increase the anesthetic efficacy of TTC for safe, effective, painless, and prolonged analgesia of the maxillary teeth in dental procedures. The hybrid system based on TTC (4%) encapsulated in nanostructured lipid carriers (NLC) and incorporated into a thermoreversible hydrogel of poloxamer 407 (TTCNLC-HG4%) displayed desirable rheological, mechanical, and mucoadhesive properties for topical application in the nasal cavity. Compared to control formulations, the use of TTCNLC-HG4% slowed in vitro permeation of the anesthetic across the nasal mucosa, maintained cytotoxicity against neuroblastoma cells, and provided a three-fold increase in analgesia duration, as observed using the tail-flick test in mice. The results obtained here open up perspectives for future clinical evaluation of the thermoreversible hybrid hydrogel, which contains TTC-loaded NLC, with the aim of creating an effective, topical, intranasal, needle-free anesthesia for use in dentistry.

Efficacy of An Aqueous Morinda citrifolia Fruit Extract-Phytosome Gel in Treating Oral Inflammatory Ulcer in Rabbit Model

2020 ◽  
Vol 21 (15) ◽  
pp. 1699-1710
Author(s):  
Sonsawan Kongpuckdee ◽  
Suwipa Ungphaiboon ◽  
Supreedee Sungkharak ◽  
Narubodee Phadoongsombut ◽  
Sirima Mahattanadul
Keyword(s):  
Ulcer Healing ◽  
Healing Process ◽  
Rabbit Model ◽  
Oral Ulcer ◽  
Poloxamer 407 ◽  
Gelling Agent ◽  
Total Phenolic ◽  
Fruit Extract ◽  
Topical Gel ◽  
Daily Application

Background: Oral inflammatory ulcers are one of the common complaints of patients attending out-patient clinics. Previous in vivo studies had shown that an Aqueous M. citrifolia Fruit Extract (AMFE) possessed anti-inflammatory and ulcer healing activities. Therefore, a standardized topical bioadhesive gel containing AMFE-phytosome was developed and determined for its oral ulcer healing efficacy in a rabbit model. Methods: The AMFE phytosome (AMFE-P) was prepared by a complexation method with the required amount of AMFE: Phosphatidylcholine: Tween 80 to weigh ratio of 2:1:0.2. Poloxamer 407 was used as a gelling agent. The oral ulcer was induced in male New Zealand white rabbits by topical application of acetic acid. Each test compound was applied to the ulcer for 10 days beginning on the second day after the ulcer induction. Complete ulcer healing on the specimen obtained on day 12 was observed histologically using the histological scoring protocol. Results: The optimized gel containing AMFE-P equivalent to AMFE 10%w/w (10%AMFE-P gel) showed the best bioadhesive gel quality, a smooth and homogeneous texture with an optimum viscosity and pH range used in human oral cavity, a good physical and chemical stability and the highest percentage cumulative release of total phenolic and scopoletin content. It was found that a daily application of 10% AMFE-P gel exerted a superior ulcer healing efficacy and a significantly rapid ulcer healing process than a twice daily application of topical gel containing AMFE 10%w/w or chlorhexidine 0.2%. Conclusion: These findings demonstrated that 10% AMFE-P gel has potential as a safe and effective alternative therapeutic agent for oral ulcers.

scholarly journals Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 646
Author(s):  
Gábor Katona ◽  
Bence Sipos ◽  
Mária Budai-Szűcs ◽  
György Tibor Balogh ◽  
Szilvia Veszelka ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Nasal Mucosa ◽  
Drug Absorption ◽  
Cell Damage ◽  
Lipid Fraction ◽  
Poloxamer 407 ◽  
Nasal Drug Delivery

The aim of this study was to develop an intranasal in situ thermo-gelling meloxicam-human serum albumin (MEL-HSA) nanoparticulate formulation applying poloxamer 407 (P407), which can be administered in liquid state into the nostril, and to increase the resistance of the formulation against mucociliary clearance by sol-gel transition on the nasal mucosa, as well as to improve drug absorption. Nanoparticle characterization showed that formulations containing 12–15% w/w P407 met the requirements of intranasal administration. The Z-average (in the range of 180–304 nm), the narrow polydispersity index (PdI, from 0.193 to 0.328), the zeta potential (between −9.4 and −7.0 mV) and the hypotonic osmolality (200–278 mOsmol/L) of MEL-HSA nanoparticles predict enhanced drug absorption through the nasal mucosa. Based on the rheological, muco-adhesion, drug release and permeability studies, the 14% w/w P407 containing formulation (MEL-HSA-P14%) was considered as the optimized formulation, which allows enhanced permeability of MEL through blood–brain barrier-specific lipid fraction. Cell line studies showed no cell damage after 1-h treatment with MEL-HSA-P14% on RPMI 2650 human endothelial cells’ moreover, enhanced permeation (four-fold) of MEL from MEL-HSA-P14% was observed in comparison to pure MEL. Overall, MEL-HSA-P14% can be promising for overcoming the challenges of nasal drug delivery.

Sign in / Sign up

Export Citation Format

Share Document